Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5488536 | 0.85 | SMN1; SMN2 (0.55) | SMN1; SMN2ALDH1A1HTTMAPTMEN1 | |
| SCHEMBL5478939 | 0.74 | SMN1; SMN2 (0.56) | SMN1; SMN2ALDH1A1GAAHTTMAPT | |
| SCHEMBL5486789 | 0.71 | SMN1; SMN2 (0.56) | SMN1; SMN2ALDH1A1HTTMAPTMEN1 | |
| SCHEMBL5482126 | 0.71 | SMN1; SMN2 (0.56) | SMN1; SMN2ALDH1A1HTTMAPTMEN1 | |
| SCHEMBL5482648 | 0.68 | SMN1; SMN2 (0.62) | SMN1; SMN2ALDH1A1HTTMAPTLMNA | |
| SCHEMBL5478145 | 0.67 | SMN1; SMN2 (0.60) | SMN1; SMN2ALDH1A1HTTMAPTMEN1 | |
| SCHEMBL5474337 | 0.67 | SMN1; SMN2 (0.60) | SMN1; SMN2ALDH1A1GAAHTTMAPT | |
| SCHEMBL5488988 | 0.67 | CNR1 (0.50) | HTTMAPTLMNAMEN1KMT2A | |
| SCHEMBL5486000 | 0.66 | CNR1 (0.63) | SMN1; SMN2ALDH1A1MAPK1GAAHTT | |
| SCHEMBL5482300 | 0.66 | SMN1; SMN2 (0.52) | SMN1; SMN2ALDH1A1GAAHTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070299102-A1 | Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer | TOPO TARGET A/S (DK) | 2007-12-27 | — | — | US | claimed |
| US-20070299102-A1 | Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer | TOPO TARGET A/S (DK) | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299102-A1 | Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer | MTOR, RICTOR, CDK4 | SMN1; SMN2 234/4885ALDH1A1 2650/4885MAPK1 346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.